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(gamma = 0.636, p = 0.04); the presence of LF with AGC – with
the Grade (gamma = 0.530, p = 0.03), histological type
(gamma = 0.726, p = 0.02) and the degree of dysplasia GM
(gamma = 0.833, p = 0.001). Multiple LF, focal LI and LF with AGC
bit more often observed at grade G3-4 and signet ring cell carci-
noma (SRCC) (LF 0%, 25%, 42.9% and 55.6%, p = 0.23, LI in50%,
42.9%, 100%, 66.7%, p = 0.07 and LF with AGC 12.5%, 0%, 50%,
28.6%, p = 0.17, respectively, when G1 , G2, G3-4 and SRCC) and
diffuse type gastric cancer (LF 20% and 50%, p = 0.12 in 60% and
81.2%, p = 0.23 and LF with AGC 10% and 41.2%, p = 0.07, respec-
tively, for the intestinal and diffuse type gastric cancer). Focal LI
and LF with AGC were more common in moderate and severe
dysplasia of the gastric epithelium (LI 58.3% and 84.6%, p = 0.14
and LF with AGC 50%, 8.3%, p = 0. 02).
A decrease in the three-year relapse-free survival in multiple
LF from 75% to 40%, p = 0.04 and in the presence of focal
LI – 83.3% to 57.9%, p = 0.17 were observed. In the presence of
focal LI, a decrease in the three-year overall survival from 100%
to 73.7% was also observed (p = 0.14).
The findings suggest that B-cells may be associated with the
factors of GC progression. It is important that the high density
of the diffuse B-lymphocytes was typical for early GC, whereas
the presence of LI and multiple LF in GM adjacent to tumor was
more often observed in diffuse type of GC, poorly differentiated
tumors and signet ring cell carcinoma We believed, that further
studies are needed for the understanding of the mechanisms
whereby the B-cell LI and LF may be related with the histology
type and Grade of GC.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.111
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In vitro Epstein-Barr virus (EBV) infects B-cells resulting in
immortalization, In vivo the virus resides latent in resting
B-cells. Rarely the EBV-host cell interaction may contribute to
development of malignant lymphoma. It is well known that both
c-myc translocation and the viral infection are observed in
patients with EBV+ Burkitt’s lymphoma (BL). Proteoglycans (PGs)
are complex glycosylated proteins. They are key components of
ECM and play a critical role in cell–cell and cell–matrix interac-
tions. Disruptions of such interactions will affect B cell interac-
tion with surrounding stroma and may thus perturb the cell
phenotypes. The purpose of this study was to investigate
expressinon of proteoglycans in EBV+ cell lines with different ori-
gins and phenotypes.
We analysed the expression of 12 of the main proteoglycans in
primary B cells, lymphoblastoid cell lines (LCLs) generated by EBV
infection of normal human B cells in vitro and EBV-positive BL cell
lines. An EBV-negative BL cell line was used for reference.
According to RT-PCR analysis, primary B-lymphocytes
expressed different PGs, mainly serglycin, CD44, perlecan and
syndecan-1. The high expression of PGs in normal B cells proba-
bly reflects interactions of these cells with the neighbouring cells
and microenvironment. B cell lines which carry EBV, in general,
showed lower levels of PGs. The PGs expression pattern was sim-
ilar in LCLs and in primary B cells, however, distinguished by high
levels of perlecan and serglycin and low expression of CD44 in
LCLs. BL cells showed the most significant down-regulation of
PGs compared to primary B cells. Therewas a correlation between
the type of EBV latency program, and PGs expression. Serglycin
was expressed at a low levels in BL-cells with EBV latency
III-program compared to LCLs, while in EBV latency I BL cells both
serglycin and perlecan were down-regulated.
Cells with latency I-program show general hypermethylation
of the cellular genome in contrast to cells with latency
III-program. Thus we explored the possibility of epigenetic
regulation of the PG-coding genes by treating cells with
50-deoxyazacytidine (5-AzaC, a demethylating agent) and Tricho-
statin A (TSA, a chromatin structure modulator). There was no
significant change in PGs expression upon this treatment in LCLs
or in EBV latency III BL cells, while EBV latency I BL cells showed
up-regulation of several PGs. This suggests that PGs expression is
at least partly regulated by epigenetic mechanisms. Interestingly
EBV latency is also partly regulated at the epigenetic level.
Similar trends were observed for the key ECM components
(collagen 1A1, fibronectin and elastin). Normal B lymphocytes
expressed collagen, fibronectin and elastin, whereas LCLs and
BL cells showed no expression of these. Treatment of these cells
with 5-AzaC or TSA resulted in similar changes in PGs expression
patterns. Up-regulation of ECM components was detected only in
EBV latency I BL cells.
Taken together, our data show that proteoglycans are
expressed in primary B lymphocytes whereas they are not or only
partly expressed in EBV-carrying cell lines, depending on their
latency program. Expression of PGs in latency I BL cells is silenced
due to hypermethylation, but by another mechanim in latency III
BL cells. These results show that PGs expression patterns follow
the EBV latency programs . It will be highly interesting to further
investigate if EBV and its transformation associated genes are
directly involved in control of PGs, as well as how PGs may con-
tribute to major phenotypic properties of EBV-carrying cell lines,
such as adhesion, migration and growth in soft agarose – a prop-
erty associated with the malignant phenotype of BLs.
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Background: For single nucleotide polymorphism – SNP
(SNP – Single Nucleotide Polymorphism) is characterized by
phenomenon of allelic imbalance (AI). The phenomenon of allelic
imbalanced (AI) is typical of many genes in different malignan-
cies. Allelic imbalanced may result allelic deletions (loss of one
copy of the locus) or amplification of one allele, resulting in only
a single allelic variant of SNP is determined in the tumor in the
PCR. Phenomenon of AI in tumors of breast cancer (BC) is consid-
ered in one or more genes. The phenomenon of AI during
chemotherapy (CT) and especially in the longer format of the
gene had not previously been studied.
Thus, the aim of this work was to study microarray imbal-
anced allele in mammary tumors during neoadjuvant chemother-
apy (NCT).
Materials and methods: The study included 26 breast cancer
patients with stage IIA – IIIC. The patients in the neoadjuvant
mode received 2–4 courses of chemotherapy regimens FAC or
CAX. DNA from 26 paired samples before treatment and opera-
tional samples were isolated by dialing QIAampDNA miniKit
(Qiagen, Germany). Microarray analysis was performed on DNA
chips of high density company Affymetrix (USA) CytoScanTM
HD Array, which contains more than 750 thousand SNP. Microar-
ray analysis was performed on SNP genotypes DNA tumor tissue
before and after treatment for each patient and recorded as
change occurring allelic imbalanced tumor tissue genotype
(AA > AB > AB AA BB > AB > AB BB) during therapy.
Results: The frequency of the AI in breast tumor during NCT
was highly variable (within 0.9–66.5%) of the studied SNP
(6850 – 497,979 SNP). For each patient, frequency shift genotype
(homozygous in heterozygous genotype, and vice versa) was cal-
culated as a percentage of all the shifts. Changes in the wild or
mutant heterozygous genotypes (AA or BB > AB) were combined
into one group; the second group was the sum of the change in
the heterozygous genotype homozygous wild genotype or the
mutant (AB > AA or BB). We have found that the direction of the
AI was significantly associated effect of NCT. In the group of
patients with partial regression, the direction of AI change from
homozygous to heterozygous genotype often occurs (AA or
BB > AB) (9/14, 64%), whereas patients with no response to the
NCT (with stabilization or progression) have the opposite effect.
All these patients (12/12 cases) have the direction of the change
of AI from heterozygous genotype to homozygous (AA or AB >
BB) (p = 0.00071). AI during chemotherapy at the level of the
marked tendency (Log-rank test, p = 0.062) is associated with
5-year metastasis-free survival. Low metastasis-free survival rate
is observed in patients with AI in the direction of the change from
the heterozygous to homozygous genotype, while 100% survival
is noted in patients with change from homozygous to heterozy-
gous genotypes, and this imbalanced t allele is a favorable prog-
nostic factor.
Conclusion: Allelic imbalanced in breast tumor during NCT
phenomenon is massive and may affect up to 67% of SNP. AI
may occur in the direction of change from homozygous to
heterozygous genotype, and it is associated with a good response
to treatment and 100% metastasis-free survival. Apparently, this
can be explained by the fact that the change from homozygous
genotypes to heterozygous occur due to partial destruction of
tumor cells by chemotherapy, resulting in the increase of stromal
elements. In contrast, AI in the direction change from heterozy-
gous to homozygous genotype during NCT is associated with no
response to chemotherapy due to metastasis and occurring of
new mutant clones in the tumor.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.113
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Dendritic cells (DCs) are the most potent antigen-presenting
cells, which play crucial role in initiation and maintenance of
immune response. However, DCs of high-grade glioma patients
are characterized by some functional impairment including
reduced TNFa-mediated antitumor cytotoxic activity and low
migratory activity. Tumor-produced soluble molecules can pro-
foundly affect the differentiation and maturation of DCs and
influence the functional activity of DCs. The aim of the present
study was to determine the effect of supernatants of primary
glioma cell lines on the migration and the cytotoxic activity of
healthy donor DCs. The study included 11 healthy donors and 7
patients with histologically verified glioma Grade II (2 patients)
and glioma Grade IV (5 patients). DCs were generated from
peripheral blood monocytes of healthy donors in the presence
of GM-CSF and IFN-alpha (IFN-DCs) followed by the addition of
lipopolysaccharide (LPS Escherichia coli). Primary glioma cell cul-
tures from tissue samples of studied patients were obtained by
mechanical and enzymatic (0.3% collagenase IA) disaggregation
followed by culturing in DMEM/F12 medium containing 10%
FCS. 7-day supernatants were collected upon reaching the cellular
subconfluence. Migratory capacity of donor IFN-DCs in response
to supernatants (v/v 25%) of primary glioma cell cultures was
measured in trans-well culture chamber. DCs that migrated to
the bottom chamber with medium alone as a control or with
supernatants were counted by FACS analysis using BD calibration
beads. Cytotoxic activity of donor IFN-DCs against tumor cell line
HEp-2 was studied using MTT-assay for 24 h at a ratio of DC: HEp-
2 1:1. IFN-DCs were preincubated for 2 h with supernatants of
primary glioma cell cultures. Migration index of donor IFN-DCs
to lymphoid chemokine CCL19 (100 ng/ml) was an average of
6.5 ± 2.1. Migration capacity of IFN-DCs towards concentration
gradient of primary glioma culture supernatants was significantly
higher. Supernatants of low-grade glioma cultures as well as of
high-grade glioma cultures effectively induced chemotaxis of
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